Inactive Instrument

Cubist Pharmaceuticals Inc Share Price

Stocks

End-of-day quote Nasdaq Other stock markets
- ^USD	-

09/12/14	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
09/12/14	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

09/12/14	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
09/12/14	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE
09/12/14	Merck : to take on superbugs with Cubist Pharma buy	RE
08/12/14	AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	RE
08/12/14	Apple : S&P 500 posts worst day since Oct; energy shares sink	RE
08/12/14	Cubist Pharmaceuticals : options unusually active before Merck deal	RE
06/12/14	Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	RE
20/05/13	Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	RE

13/01/15	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	BU
19/12/14	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	BU
16/12/14	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company	PR
12/12/14	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU
12/12/14	Cubist Pharmaceuticals : CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. in Connection With the Fairness of the Sale of the Company to Merck & Co.	BU

21/12/14	Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen
20/12/14	Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées
09/12/14	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin
08/12/14	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars
08/12/14	Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète

Manager	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	31/12/1996

Director	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	72	31/08/2006
Kenneth J. Martin BRD	Director/Board Member	72	24/09/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENERON PHARMACEUTICALS, INC.	+4.73%	+3.38%	+19.53%	-8.85%	66.56B
UCB	-0.12%	-1.56%	+52.68%	+227.44%	56.51B
SAMSUNG BIOLOGICS CO.,LTD.	+1.07%	+42.10%	+42.10%	+42.10%	42.98B
CSL LIMITED	+1.99%	+7.66%	-49.90%	-54.41%	40.46B
BIOGEN INC.	+3.04%	+0.04%	+62.66%	-24.40%	31.91B
MODERNA, INC.	+10.01%	+18.57%	+161.59%	-35.44%	31.65B
INCYTE CORPORATION	+2.68%	+2.73%	+70.72%	+85.52%	23.35B
INNOVENT BIOLOGICS, INC.	+3.08%	+13.05%	+9.63%	+195.27%	19.46B
SWEDISH ORPHAN BIOVITRUM AB	+0.31%	+3.67%	+67.69%	+133.50%	17.18B
Average	+2.99%	+8.76%	+48.52%	+62.30%	36.67B
Weighted average by Cap.	+2.97%	+7.31%	+42.97%	+54.72%

Employees

Sector